Pfizer-Allergan merger raises questions about future of NuMedii deal

Speculation about the fallout from Pfizer ($PFE) and Allergan's ($AGN) $160 billion megamerger has begun. The San Francisco Business Times put together a list of companies that could be affected by the deal that includes NuMedii, the digital drug discovery player that struck a collaboration with Allergan in September. Article

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.